angioplasty

The use of a paclitaxel eluting balloon in small vessels

Original title:&nbsp;A Randomized Multicenter Study Comparing a Paclitaxel Drug-Eluting Balloon With a Paclitaxel-Eluting Stent in Small Coronary Vessels. The BELLO (Balloon Elution and Late Loss Optimization) Study&nbsp;Reference:&nbsp;Referencia: Azeem Latib et al J Am Coll Cardiol 2012;()doi:10.1016/j.jacc.2012.09.020 The utility of paclitaxel-eluting balloons to treat in-stent restenosis is known but data for novo lesions is more limited.&nbsp;<a href="https://solaci.org/en/2012/11/16/n-3774/" title="Read more" >...</a>

A new paradigm in the treatment of in-stent restenosis?

Original title:&nbsp;ISAR DESIRE 3: Drug-eluting balloon is best option for restenosis of limus-eluting stents&nbsp;Reference:&nbsp;Dr Robert Byrne. TCT 2012. Miami, Fl. The first of the ISAR DESIRE trials showed that drug-eluting stents (DES) were the best strategy for treating restenosis of a bare metal stent, the second ISAR DESIRE trial tested the hypothesis of changing or<a href="https://solaci.org/en/2012/11/11/n-3746/" title="Read more" >...</a>

Drug eluting balloon; a valid alternative to treat in-stent restenosis in the superficial femoral artery

Original title:&nbsp;Drug-Eluting Balloon for Treatment of Superficial Femoral Artery In-Stent Restenosis&nbsp;Reference:&nbsp;Eugenio Stabile et al. Journal of the American College of Cardiology 60:1739&ndash;42 (2012) Drug eluting balloon; a valid alternative to treat in-stent restenosis in the superficial femoral artery&nbsp; This prospective registry included 39 patients who received Paclitaxel-Eluting Balloon Angioplasty, (IN.PACT, Medtronic, Minneapolis, Minnesota), for in-stent<a href="https://solaci.org/en/2012/11/09/n-3739/" title="Read more" >...</a>

Diabetics with multivessel, must keep waiting.

Original title:&nbsp;Strategies for Multivessel Revascularization in Patients with Diabetes. The FREEDOM Trial.&nbsp;Reference:&nbsp;Michael E. Farkouh et al. N Engl J Med 2012. DOI: 10.1056/NEJMoa1211585 This study was designed to determine the best revascularization strategy in diabetic patients with multivessel using current techniques of angioplasty (PCI) and surgery (CABG). Randomized 1:1 diabetic patients with injuries &gt; 70%<a href="https://solaci.org/en/2012/11/08/n-3732/" title="Read more" >...</a>

Predictors of invasive versus conservative treatment in elderly patients with acute coronary syndromes.

Original title:&nbsp;Predictors of Treatment in Acute Coronary Syndromes in the Elderly: Impact on Decision Making and Clinical Outcome After Interventional Versus Conservative Treatment.&nbsp;Reference:&nbsp;Harald Rittger et al. Catheterization and Cardiovascular Interventions 80:735&ndash;743 (2012). This study, recently published in Cath Cardiovasc Interven, was performed to determine the factors that helped physicians decide to be conservative or invasive.<a href="https://solaci.org/en/2012/11/01/n-3711/" title="Read more" >...</a>

Global Risk Score for stratification of patients with multivessel coronary artery disease: A wider look

Reference: Serruys et al J Am Coll Cardiol Intv 2012;5:606&ndash;17 SYNTAX Analysis study demonstrates the utility of a new risk score for patients stratification with left main coronary artery or multivessel disease. Numerous studies have demonstrated the value of SYNTAX score to stratify risk of angioplasty and decision-making (angioplasty versus surgery) in patients with multivessel<a href="https://solaci.org/en/2012/10/01/n-3900/" title="Read more" >...</a>

To discontinue clopidogrel after a year of infarction can be risky

Reference: Charlot et al. European Heart Journal 2012 (in press). International guideline recommendations approve giving dual antiplatelet therapy for a period of not less than 12 months after acute myocardial infarction. However, the benefit is unknown if the therapy is extended beyond 12 months. Perhaps its extension could be particularly useful in patients receiving pharmacological<a href="https://solaci.org/en/2012/10/01/n-3942/" title="Read more" >...</a>

Renal failure in acute myocardial infarction

Reference:&nbsp;Fox y colaboradores. Short-term Outcomes of Acute Myocardial Infarction in Patients with Acute Kidney Injury: A Report from the National Cardiovascular Data Registry. Circulation 2012 (in press). The presence of chronic renal failure is common in patients referred for angioplasty. Its presence is associated with increased mortality and bleeding. However, the prevalence is unknown as<a href="https://solaci.org/en/2012/09/01/n-3949/" title="Read more" >...</a>

Hyperglycemia on admission, an excess risk for infarction

Reference: Planer et al. International Journal of Cardiology 2012 (in press) Prognosis of patients enrolled in acute myocardial infarction with ST segment elevation (STEMI) has improved markedly, particularly as a result of reperfusion therapy. Despite these improvements, patients with diabetes mellitus (DM) are a high risk group in the short and long term compared with<a href="https://solaci.org/en/2012/09/01/n-3956/" title="Read more" >...</a>

In patients with stroke history, Ticagrelor is superior to Clopidogrel

James SK, Storey RF, Khurmi N, et al. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes and a History of Stroke or Transient Ischemic Attack. Circulation 2012. A sub-analysis of the PLATO study demonstrated similar superiority and the safety of ticagrelor in all patients, regardless of any previous history of stroke. Ticagrelor versus clopidogrel:<a href="https://solaci.org/en/2012/09/01/n-3984/" title="Read more" >...</a>

Top